Endocrine Abstracts

Objectives: Endogenous Cushing’s syndrome (CS) is a rare, chronic condition that results in high morbidity, caused by prolonged exposure to elevated levels of circulating free cortisol. A previous comparative analysis showed osilodrostat increases the odds of complete response (CR; mean urinary free cortisol [mUFC] ≤ 1.0 x the upper limit of normal) at Weeks 12 and 36 vs metyrapone1; however, analyses were limited by small osilodrostat effective sample si...